Literature DB >> 21106736

Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination.

Yongjun Wen1, Hualei Wang, Hua Wu, Fuhe Yang, Ralph A Tripp, Robert J Hogan, Zhen F Fu.   

Abstract

Our previous studies indicated that recruitment and/or activation of dendritic cells (DCs) is important in enhancing the protective immune responses against rabies virus (RABV) (L. Zhao, H. Toriumi, H. Wang, Y. Kuang, X. Guo, K. Morimoto, and Z. F. Fu, J. Virol. 84:9642-9648). To address the importance of DC activation for RABV vaccine efficacy, the genes for several DC recruitment and/or activation molecules, e.g., granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage-derived chemokine (MDC), and macrophage inflammatory protein 1α (MIP-1α), were individually cloned into RABV. The ability of these recombinant viruses to activate DCs was determined in vitro and in vivo. Infection of mouse bone marrow-derived DCs with each of the recombinant viruses resulted in DC activation, as shown by increased surface expression of CD11c and CD86 as well as an increased level of alpha interferon (IFN-α) production compared to levels observed after infection with the parent virus. Intramuscular infection of mice with each of the viruses recruited and/or activated more DCs and B cells in the periphery than infection with the parent virus, leading to the production of higher levels of virus-neutralizing antibodies. Furthermore, a single immunization with recombinant RABV expressing GM-CSF or MDC protected significantly more mice against intracerebral challenge with virulent RABV than did immunization with the parental virus. Yet, these viruses did not show more virulence than the parent virus, since direct intracerebral inoculation with each virus at up to 1 × 10(7) fluorescent focus units each did not induce any overt clinic symptom, such as abnormal behavior, or any neurological signs. Together, these data indicate that recombinant RABVs expressing these molecules activate/recruit DCs and enhance protective immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106736      PMCID: PMC3028913          DOI: 10.1128/JVI.01552-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Vero-cell rabies vaccine produced using serum-free medium.

Authors:  Neuza M Frazatti-Gallina; Regina M Mourão-Fuches; Rosana L Paoli; Maria L N Silva; Cosue Miyaki; Elizabeth J G Valentini; Isaias Raw; Hisako G Higashi
Journal:  Vaccine       Date:  2004-12-09       Impact factor: 3.641

2.  Dendritic cells induced in the presence of GM-CSF and IL-5.

Authors:  Huanfa Yi; Lianjun Zhang; Yu Zhen; Xiaoyan He; Yong Zhao
Journal:  Cytokine       Date:  2007-03-26       Impact factor: 3.861

Review 3.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

4.  Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice.

Authors:  Milosz Faber; Michael Bette; Mirjam A R Preuss; Rojjanaporn Pulmanausahakul; Jennifer Rehnelt; Matthias J Schnell; Bernhard Dietzschold; Eberhard Weihe
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  GM-CSF Biology.

Authors:  John A Hamilton; Gary P Anderson
Journal:  Growth Factors       Date:  2004-12       Impact factor: 2.511

Review 6.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus.

Authors:  Milosz Faber; Marie-Luise Faber; Jianwei Li; Mirjam A R Preuss; Matthias J Schnell; Bernhard Dietzschold
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein.

Authors:  Mutsuyo Takayama-Ito; Ken-Ichi Inoue; Yoko Shoji; Satoshi Inoue; Toshio Iijima; Takeo Sakai; Ichiro Kurane; Kinjiro Morimoto
Journal:  Virus Res       Date:  2006-02-13       Impact factor: 3.303

Review 9.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know.

Authors:  Yufang Shi; Catherine H Liu; Arthur I Roberts; Jyoti Das; Guangwu Xu; Guangwen Ren; Yingyu Zhang; Liying Zhang; Zeng Rong Yuan; Hung Sheng William Tan; Gobardhan Das; Satish Devadas
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

10.  Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway.

Authors:  Jianwei Li; James P McGettigan; Milosz Faber; Matthias J Schnell; Bernhard Dietzschold
Journal:  Vaccine       Date:  2007-11-29       Impact factor: 3.641

View more
  48 in total

1.  Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene.

Authors:  Hualei Wang; Hongli Jin; Na Feng; Xuexing Zheng; Ling Li; Yinglin Qi; Meng Liang; Yongkun Zhao; Tiecheng Wang; Yuwei Gao; Changchun Tu; Ningyi Jin; Songtao Yang; Xianzhu Xia
Journal:  Virus Genes       Date:  2015-02-28       Impact factor: 2.332

2.  A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.

Authors:  Celestine N Wanjalla; Elizabeth F Goldstein; Christoph Wirblich; Matthias J Schnell
Journal:  Virology       Date:  2012-02-16       Impact factor: 3.616

3.  A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells.

Authors:  Zhao Wang; Mingming Li; Ming Zhou; Yajing Zhang; Jie Yang; Yandi Cao; Kunlun Wang; Min Cui; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

4.  Exhaustive Exercise Does Not Affect Humoral Immunity and Protection after Rabies Vaccination in a Mouse Model.

Authors:  Lun Xia; Minrui Li; Yajing Zhang; Juncheng Ruan; Jie Pei; Jiale Shi; Zhen F Fu; Ling Zhao; Ming Zhou; Dayong Tian
Journal:  Virol Sin       Date:  2018-03-28       Impact factor: 4.327

5.  Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination.

Authors:  Yingying Li; Ming Zhou; Zhaochen Luo; Yachun Zhang; Min Cui; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection.

Authors:  Ying Huang; Zhenhai Chen; Junhua Huang; ZhenFang Fu; Biao He
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

7.  Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the Central Nervous System (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues.

Authors:  Jianwei Li; Adam Ertel; Carla Portocarrero; Darryll A Barkhouse; Bernhard Dietzschold; D Craig Hooper; Milosz Faber
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

8.  Recombinant rabies virus expressing IL-15 enhances immunogenicity through promoting the activation of dendritic cells in mice.

Authors:  Tiange Chen; Yajing Zhang; Zhao Wang; Jie Yang; Mingming Li; Kunlun Wang; Min Cui; Zhen F Fu; Ling Zhao; Ming Zhou
Journal:  Virol Sin       Date:  2017-08-29       Impact factor: 4.327

9.  Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection.

Authors:  Qingqing Chai; Wen Q He; Ming Zhou; Huijun Lu; Zhen F Fu
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Role of the blood-brain barrier in rabies virus infection and protection.

Authors:  Lihua Wang; Yuxi Cao; Qing Tang; Guodong Liang
Journal:  Protein Cell       Date:  2013-12       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.